{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:18:07Z","timestamp":1791195487448,"version":"4.1.0"},"reference-count":110,"publisher":"Impact Journals, LLC","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,9,29]]},"DOI":"10.18632\/oncotarget.5025","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T17:43:03Z","timestamp":1443548583000},"page":"26826-26840","source":"Crossref","is-referenced-by-count":56,"title":["Notch signaling deregulation in multiple myeloma: A rational molecular target"],"prefix":"10.18632","volume":"6","author":[{"given":"Michela","family":"Colombo","sequence":"first","affiliation":[{"name":"Department of Health Sciences, Universit\u00e0 degli Studi di Milano, 20142 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Galletti","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, Universit\u00e0 degli Studi di Milano; Hematology, Fondazione C\u00e0 Granda IRCCS Policlinico, 20122 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Garavelli","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Universit\u00e0 degli Studi di Milano, 20142 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Platonova","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, Universit\u00e0 degli Studi di Milano; Hematology, Fondazione C\u00e0 Granda IRCCS Policlinico, 20122 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Paoli","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Universit\u00e0 degli Studi di Milano, 20142 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Basile","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Universit\u00e0 degli Studi di Milano, 20142 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Taiana","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, Universit\u00e0 degli Studi di Milano; Hematology, Fondazione C\u00e0 Granda IRCCS Policlinico, 20122 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Neri","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, Universit\u00e0 degli Studi di Milano; Hematology, Fondazione C\u00e0 Granda IRCCS Policlinico, 20122 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Chiaramonte","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Universit\u00e0 degli Studi di Milano, 20142 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,8,13]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Anderson","year":"2011","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Dispenzieri","year":"2014","journal-title":"Lancet Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"key":"4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Chen","year":"2010","journal-title":"Leukemia"},{"key":"5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.blre.2011.01.005","article-title":"Plasma cell leukemia","volume":"25","author":"Fonseca","year":"2011","journal-title":"Blood Rev"},{"key":"6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Comenzo","year":"2013","journal-title":"Leukemia"},{"key":"7","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Kuehl","year":"2009","journal-title":"Leukemia"},{"key":"8","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Bergsagel","year":"2012","journal-title":"J Clin Invest"},{"key":"9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Davies","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Rosenberg","year":"2014","journal-title":"Cancer Cell"},{"key":"11","article-title":"Molecular spectrum of BRAF, NRAS, and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation","author":"Neri","year":"2015","journal-title":"Oncotarget"},{"key":"12","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/jbmr.2443","article-title":"Association of QCT bone mineral density and bone structure with vertebral fractures in patients with multiple myeloma","volume":"30","author":"Gl\u00fcer","year":"2015","journal-title":"J Bone Miner Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12185-011-0949-x","article-title":"Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma","volume":"94","author":"Abe","year":"2011","journal-title":"Int J Hematol"},{"key":"14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/asheducation-2002.1.214","article-title":"Multiple Myeloma","volume":"2002","author":"Roodman","year":"2002","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"15","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.1989.7.12.1909","article-title":"Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease","volume":"7","author":"Alexandre","year":"1989","journal-title":"J Clin Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1385\/MO:19:3:133","article-title":"Correlation of sera TNF-\u03b1 with percentage of bone marrow plasma cells, LDH, \u03b22-microglobulin, and clinical stage in multiple myeloma","volume":"19","author":"Juri\u0161i\u0107","year":"2002","journal-title":"Med Oncol"},{"key":"17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05018.x","article-title":"Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation","volume":"126","author":"Schneider","year":"2004","journal-title":"Br J Haematol"},{"key":"18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.exphem.2004.03.015","article-title":"New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL)","volume":"32","author":"Rizzoli","year":"2004","journal-title":"Exp Hematol"},{"key":"19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2010.08141.x","article-title":"Advances in the understanding of myeloma bone disease and tumour growth","volume":"149","author":"Yaccoby","year":"2010","journal-title":"Br J Haematol"},{"key":"20","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMe1407442","article-title":"Current treatment for multiple myeloma","volume":"371","author":"Rosenblatt","year":"2014","journal-title":"N Engl J Med"},{"key":"21","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","article-title":"International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation","volume":"117","author":"Blad\u00e9","year":"2011","journal-title":"Blood"},{"key":"22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Cavo","year":"2014","journal-title":"J Clin Oncol"},{"key":"23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/leu.2013.350","article-title":"New drugs and novel mechanisms of action in multiple myeloma in 2013. a report from the International Myeloma Working Group (IMWG)","volume":"28","author":"Dimopoulos","year":"2014","journal-title":"Leukemia"},{"key":"24","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.hoc.2007.08.007","article-title":"The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies","volume":"21","author":"Anderson","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"25","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.18632\/oncotarget.1497","article-title":"Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms","volume":"4","author":"Chang","year":"2013","journal-title":"Oncotarget"},{"key":"26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cell.2013.03.024","article-title":"ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencing","volume":"153","author":"Nishikura","year":"2013","journal-title":"Cell"},{"key":"27","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1073\/pnas.1213021110","article-title":"ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia","volume":"110","author":"Morris","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0012-1606(85)90331-8","article-title":"The molecular genetics of the Notch locus in Drosophila melanogaster","volume":"107","author":"Artavanis-Tsakonas","year":"1985","journal-title":"Dev Biol"},{"key":"29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cell.2009.03.045","article-title":"The canonical Notch signaling pathway: unfolding the activation mechanism","volume":"137","author":"Ilagan","year":"2009","journal-title":"Cell"},{"key":"30","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1242\/dev.01074","article-title":"Notch signaling: control of cell communication and cell fate","volume":"131","author":"Lai","year":"2004","journal-title":"Development"},{"key":"31","first-page":"1","article-title":"The Notch pathway in hematopoietic stem cells","volume":"360","author":"Espinosa","year":"2012","journal-title":"Curr Top Microbiol Immunol"},{"key":"32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1074-7613(00)80105-3","article-title":"Notch1 expression in early lymphopoiesis influences B versus T lineage determination","volume":"11","author":"Pear","year":"1999","journal-title":"Immunity"},{"key":"33","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.bcp.2010.03.026","article-title":"Notch signaling: emerging molecular targets for cancer therapy","volume":"80","author":"Liu","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2011.05.009","article-title":"Notch-ing from T-cell to B-cell lymphoid malignancies","volume":"308","author":"Chiaramonte","year":"2011","journal-title":"Cancer Lett"},{"key":"35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.canlet.2004.07.022","article-title":"A wide role for NOTCH1 signaling in acute leukemia","volume":"219","author":"Comi","year":"2005","journal-title":"Cancer Lett"},{"key":"36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Aster","year":"2004","journal-title":"Science"},{"key":"37","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/leu.2013.6","article-title":"Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes","volume":"27","author":"Chiaramonte","year":"2013","journal-title":"Leukemia"},{"key":"38","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1182\/blood-2003-07-2254","article-title":"Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells","volume":"103","author":"D\u00f6rken","year":"2004","journal-title":"Blood"},{"key":"39","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.humpath.2010.05.002","article-title":"Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"41","author":"Dominis","year":"2010","journal-title":"Hum Pathol"},{"key":"40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.exphem.2008.08.006","article-title":"Identification of primary MAFB target genes in multiple myeloma","volume":"37","author":"Bast","year":"2009","journal-title":"Exp Hematol"},{"key":"41","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1182\/blood-2003-12-4114","article-title":"Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines","volume":"104","author":"Coignet","year":"2004","journal-title":"Blood"},{"key":"42","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0002-9440(10)62491-1","article-title":"Skeletrophin, a novel ubiquitin ligase to the intracellular region of Jagged-2, is aberrantly expressed in multiple myeloma","volume":"166","author":"Ohtsuki","year":"2005","journal-title":"Am J Pathol"},{"key":"43","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1158\/0008-5472.CAN-08-3467","article-title":"Loss of the SMRT\/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma","volume":"69","author":"Coignet","year":"2009","journal-title":"Cancer Res"},{"key":"44","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Pineda-Roman","year":"2006","journal-title":"Blood"},{"key":"45","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood-2007-03-079855","article-title":"Notch target Hes5 ensures appropriate Notch induced T- versus B-cell choices in the thymus","volume":"111","author":"Bernstein","year":"2008","journal-title":"Blood"},{"key":"46","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/leu.2013.27","article-title":"Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4\/SDF-1","volume":"27","author":"Chiaramonte","year":"2013","journal-title":"Leukemia"},{"key":"47","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2007-07-102632","article-title":"Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy","volume":"111","author":"Nefedova","year":"2008","journal-title":"Blood"},{"key":"48","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1158\/1535-7163.MCT-10-0372","article-title":"Combined inhibition of Notch signaling and Bcl-2\/Bcl-xL results in synergistic anti-myeloma effect","volume":"9","author":"Nefedova","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"49","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/path.3015","article-title":"Notch1 regulates chemotaxis and proliferation by controlling the chemokine receptors 5 and 9 in T-cell acute lymphoblastic leukemia","volume":"226","author":"Chiaramonte","year":"2012","journal-title":"J Pathol"},{"key":"50","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/nature08020","article-title":"CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia","volume":"459","author":"Newcomb","year":"2009","journal-title":"Nature"},{"key":"51","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1189\/jlb.1204746","article-title":"A novel role for Notch ligand Delta-1 as a regulator of human Langerhans cell development from blood monocytes","volume":"78","author":"Shiku","year":"2005","journal-title":"J Leukoc Biol"},{"key":"52","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.imlet.2005.11.002","article-title":"Induction of chemokine receptor expression during early stages of T cell development","volume":"104","author":"Rolink","year":"2006","journal-title":"Immunol Lett"},{"key":"53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrclinonc.2015.61","article-title":"Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update","volume":"12","author":"Ivy","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"54","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Jones","year":"2008","journal-title":"Cancer Res"},{"key":"55","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/sj.leu.2403513","article-title":"The SCID-rab model: a novelsystem for primary human myeloma demonstrating growth of CD138-expressing malignant cells","volume":"18","author":"Yaccoby","year":"2004","journal-title":"Leukemia"},{"key":"56","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/leu.2011.332","article-title":"Dll1\/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation","volume":"26","author":"Van Valckenborgh","year":"2012","journal-title":"Leukemia"},{"key":"57","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bcmd.2012.01.006","article-title":"Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells","volume":"48","author":"Pellat-Deceunynck","year":"2012","journal-title":"Blood Cells Mol Dis"},{"key":"58","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbrc.2012.10.071","article-title":"Dll1\/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma","volume":"428","author":"Van Valckenborgh","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"59","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pathol-011110-130249","article-title":"Pathogenesis of myeloma","volume":"6","author":"Carrasco","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"60","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.leukres.2013.06.026","article-title":"Interleukin-6 and JAK2\/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells","volume":"37","author":"Cao","year":"2013","journal-title":"Leuk Res"},{"key":"61","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.12266","article-title":"A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","volume":"161","author":"Hall","year":"2013","journal-title":"Br J Haematol"},{"key":"62","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood.V98.2.428","article-title":"Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration","volume":"98","author":"Anderson","year":"2001","journal-title":"Blood"},{"key":"63","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00432-013-1534-x","article-title":"Dll4-Notch signaling in regulation of tumor angiogenesis","volume":"140","author":"Lu","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"64","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12307-011-0072-9","article-title":"Angiogenesis and Multiple Myeloma","volume":"4","author":"Bonomini","year":"2011","journal-title":"Cancer Microenviron"},{"key":"65","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2011-10-386789","article-title":"Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma","volume":"120","author":"Wang","year":"2012","journal-title":"Blood"},{"key":"66","doi-asserted-by":"crossref","first-page":"10393","DOI":"10.18632\/oncotarget.2084","article-title":"Notch signaling drives multiple myeloma induced osteoclastogenesis","volume":"5","author":"Chiaramonte","year":"2014","journal-title":"Oncotarget"},{"key":"67","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1210\/en.2008-0140","article-title":"Notch inhibits osteoblast differentiation and causes osteopenia","volume":"149","author":"Canalis","year":"2008","journal-title":"Endocrinology"},{"key":"68","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1038\/bcj.2014.37","article-title":"Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model","volume":"4","author":"Jundt","year":"2014","journal-title":"Blood Cancer J"},{"key":"69","first-page":"1487","article-title":"PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple Negative Breast Cancer Sensitive to a gamma-Secretase Inhibitor","volume":"2","author":"Olson","year":"2015","journal-title":"Clin Cancer Res"},{"key":"70","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"71","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/ng.3076","article-title":"Genetic landscape of esophageal squamous cell carcinoma","volume":"46","author":"Yao","year":"2014","journal-title":"Nat Genet"},{"key":"72","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2005-01-0355","article-title":"Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies","volume":"106","author":"Pear","year":"2005","journal-title":"Blood"},{"key":"73","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-12-253419","article-title":"Notch\/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression","volume":"117","author":"Zweidler-McKay","year":"2011","journal-title":"Blood"},{"key":"74","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cellsig.2013.09.021","article-title":"New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of \u03b3-secretase inhibitor resistant T-cell acute lymphoblastic leukemia","volume":"26","author":"Matherly","year":"2014","journal-title":"Cell Signal"},{"key":"75","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1084\/jem.20070876","article-title":"FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors","volume":"204","author":"Look","year":"2007","journal-title":"J Exp Med"},{"key":"76","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ng.2913","article-title":"An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia","volume":"46","author":"Jain","year":"2014","journal-title":"Nat Genet"},{"key":"77","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.284.5415.770","article-title":"Notch signaling: cell fate control and signal integration in development","volume":"284","author":"Lake","year":"1999","journal-title":"Science"},{"key":"78","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/leu.2011.192","article-title":"MRK003, a gamma-secretase inhibitor exhibits promisingpre-clinical activity in multiple myeloma and non-Hodgkin\u2019s lymphoma","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"79","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/onc.2011.212","article-title":"Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer","volume":"31","author":"Hassell","year":"2012","journal-title":"Oncogene"},{"key":"80","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ygyno.2014.03.308","article-title":"Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model","volume":"133","author":"Growdon","year":"2014","journal-title":"Gynecol Oncol"},{"key":"81","first-page":"4","article-title":"A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia\/lymphoma (T-ALL) and other leukemias","volume":"2","author":"Aster","year":"2006","journal-title":"J Clin Oncol"},{"key":"82","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1200\/JCO.2011.39.1540","article-title":"Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors","volume":"30","author":"Loboda","year":"2012","journal-title":"J Clin Oncol"},{"key":"83","first-page":"S1","article-title":"Modulation of cancer and stem cell biomarkers by the Notch Inhibitor MK-0752 added to endocrine therapy for early stage ER+ breast cancer","author":"Czaplicki","year":"2011","journal-title":"Cancer Res"},{"key":"84","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1158\/1078-0432.CCR-11-3326","article-title":"Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors","volume":"19","author":"Chang","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"85","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1158\/1535-7163.MCT-11-0938","article-title":"Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia","volume":"11","author":"Ferrando","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"86","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1158\/1078-0432.CCR-12-1379","article-title":"Biomarker and pharmacologic evaluation of the gamma-secretase inhibitor PF-03084014 in breast cancer models","volume":"18","author":"Christensen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"87","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/leu.2014.143","article-title":"The [gamma]-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells","volume":"29","author":"Colomer","year":"2015","journal-title":"Leukemia"},{"key":"88","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1158\/1078-0432.CCR-14-0607","article-title":"A Phase, I, Dose-finding Study in Patients With Advanced Solid Malignancies of the Oral Gamma-Secretase Inhibitor PF-03084014","volume":"21","author":"LoRusso","year":"2015","journal-title":"Clin Cancer Res"},{"key":"89","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2011.36.8282","article-title":"Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors","volume":"30","author":"Wang","year":"2012","journal-title":"J Clin Oncol"},{"key":"90","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ejca.2012.02.056","article-title":"A phase II study of RO4929097 in metastatic colorectal cancer","volume":"48","author":"Sullivan","year":"2012","journal-title":"Eur J Cancer"},{"key":"91","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/bjc.2013.380","article-title":"A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004\/NCI 8503)","volume":"109","author":"Ivy","year":"2013","journal-title":"Br J Cancer"},{"key":"92","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s10637-013-0001-5","article-title":"A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors","volume":"31","author":"Brana","year":"2013","journal-title":"Invest New Drugs"},{"key":"93","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10637-013-9965-4","article-title":"A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078\/CTEP 8575)","volume":"32","author":"Zhang","year":"2014","journal-title":"Invest New Drugs"},{"key":"94","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pharmthera.2013.09.005","article-title":"Targeting Notch signaling pathway in cancer: Clinical development advances and challenges","volume":"141","author":"Yang","year":"2014","journal-title":"Pharmacol Ther"},{"key":"95","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ncb1824","article-title":"Nuclear signalling by tumour-associated antigen EpCAM","volume":"11","author":"Gires","year":"2009","journal-title":"Nat Cell Biol"},{"key":"96","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrm1406","article-title":"Gamma-secretase: proteasome of the membrane?","volume":"5","author":"Ilagan","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"97","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/nature03589","article-title":"Notch signals control the fate of immature progenitor cells in the intestine","volume":"435","author":"Artavanis-Tsakonas","year":"2005","journal-title":"Nature"},{"key":"98","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/embor.2008.7","article-title":"Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2","volume":"9","author":"Radtke","year":"2008","journal-title":"EMBO Rep"},{"key":"99","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/nature08878","article-title":"Therapeutic antibody targeting of individual Notch receptors","volume":"464","author":"Finkle","year":"2010","journal-title":"Nature"},{"key":"100","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1158\/2159-8290.CD-14-0650","article-title":"NOTCH Decoys That Selectively Block DLL\/NOTCH or JAG\/NOTCH Disrupt Angiogenesis by Unique Mechanisms to Inhibit Tumor Growth","volume":"5","author":"Kitajewski","year":"2015","journal-title":"Cancer Discov"},{"key":"101","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/978-1-4614-0899-4_23","article-title":"Notch inhibition as a promising new approach to cancer therapy","volume":"727","author":"Purow","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"102","first-page":"2084","article-title":"Targeting Notch Signaling with a Notch2\/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency","volume":"21","author":"Wang","journal-title":"Clin Cancer Res"},{"key":"103","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.7602","article-title":"Phase 1b of anticancer stem cell antibody OMP-59R5 (anti-Notch2\/3) in combination with etoposide and cisplatin (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)","volume":"32","author":"Pietanza","year":"2014","journal-title":"J Clin Oncol"},{"key":"104","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/leu.2013.183","article-title":"Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts","volume":"28","author":"Indraccolo","year":"2014","journal-title":"Leukemia"},{"key":"105","doi-asserted-by":"crossref","first-page":"11244","DOI":"10.1158\/0008-5472.CAN-07-0969","article-title":"Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth","volume":"67","author":"Harris","year":"2007","journal-title":"Cancer Res"},{"key":"106","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.1158\/1078-0432.CCR-14-1373","article-title":"A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors","volume":"20","author":"Sikic","year":"2014","journal-title":"Clin Cancer Res"},{"key":"107","article-title":"Phase I study of REGN421 (R)\/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors","volume":"31","author":"Chiorean","year":"2013","journal-title":"J Clin Oncol"},{"key":"108","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/cncr.27745","article-title":"Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma","volume":"119","author":"Paton","year":"2013","journal-title":"Cancer"},{"key":"109","first-page":"570796","article-title":"Future perspectives: therapeutic targeting of notch signalling may become a strategy in patients receiving stem cell transplantation for hematologic malignancies","volume":"2011","author":"Bruserud","year":"2011","journal-title":"Bone Marrow Res"},{"key":"110","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature08543","article-title":"Direct inhibition of the NOTCH transcription factor complex","volume":"462","author":"Bradner","year":"2009","journal-title":"Nature"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:07:06Z","timestamp":1599610026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,13]]},"references-count":110,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2015,9,29]]}},"alternative-id":["5025","26308486"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.5025","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,13]]}}}